Genmab A/S/DKrGMAB
08:00
10:00
12:00
13:55
15:55
1D1W1MYTD1Y5YMAX
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, focused on the development and commercialization of antibody therapeutics for the treatment of cancer. The company is known for its proprietary antibody technologies, such as the DuoBody® and HexaBody® platforms, which enhance the efficacy and potency of treatments. Genmab's key products include DARZALEX® (daratumumab), a monoclonal antibody used in the treatment of multiple myeloma, which is marketed in collaboration with Janssen Biotech. Founded in 1999, Genmab operates a global network of offices and research facilities, including significant operations in the United States and the Netherlands. The company's strategic positioning is bolstered by its robust pipeline of investigational drugs and strategic partnerships with pharmaceutical leaders.
Ticker
DKrGMAB
Sector
Primary listing
CSE
Employees
2,681
Headquarters
Copenhagen, Denmark
Website
Genmab A/S Metrics
BasicAdvanced
kr 125B
12.64
kr 161.01
0.79
-
Price and volume
Market cap
kr 125B
Beta
0.79
52-week high
kr 2,153.00
52-week low
kr 1,282.00
Average daily volume
122K
Financial strength
Current ratio
6.034
Quick ratio
6.015
Long term debt to equity
2.191
Total debt to equity
2.469
Interest coverage (TTM)
54.85%
Profitability
EBITDA (TTM)
9,448.512
Gross margin (TTM)
94.36%
Net profit margin (TTM)
41.17%
Operating margin (TTM)
36.87%
Effective tax rate (TTM)
11.03%
Revenue per employee (TTM)
kr 9,173,020
Management effectiveness
Return on assets (TTM)
13.38%
Return on equity (TTM)
29.41%
Valuation
Price to earnings (TTM)
12.639
Price to revenue (TTM)
5.176
Price to book
21.75
Price to tangible book (TTM)
34.29
Price to free cash flow (TTM)
15.381
Free cash flow yield (TTM)
6.50%
Free cash flow per share (TTM)
132.306
Growth
Revenue change (TTM)
23.36%
Earnings per share change (TTM)
121.26%
3-year revenue growth (CAGR)
26.87%
10-year revenue growth (CAGR)
41.25%
3-year earnings per share growth (CAGR)
23.11%
10-year earnings per share growth (CAGR)
36.08%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab A/S stock?
Genmab A/S (GMAB) has a market cap of DKr125B as of December 07, 2025.
What is the P/E ratio for Genmab A/S stock?
The price to earnings (P/E) ratio for Genmab A/S (GMAB) stock is 12.64 as of December 07, 2025.
Does Genmab A/S stock pay dividends?
No, Genmab A/S (GMAB) stock does not pay dividends to its shareholders as of December 07, 2025.
When is the next Genmab A/S dividend payment date?
Genmab A/S (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab A/S?
Genmab A/S (GMAB) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.